The clinical profile in familial Mediterranean fever (FMF), including its major manifestation, amyloidosis, is influenced by MEFV allelic heterogeneity and other genetic and/or environmental factors. In this study, we analyzed the contribution of genotypes at the MEFV and SAA1 loci to disease severity and to the development of amyloidosis, and further defined the factors affecting the clinical profile of FMF.

Methods

We investigated a sample of 277 FMF patients (154 men and 123 women), including 62 patients with nephropathic amyloidosis, in whom both FMF alleles had been identified. A detailed chart review, interview, and physical examination were undertaken to determine the patients' demographic characteristics, medical history, clinical manifestations, and treatment. The disease severity score was calculated from the Tel-Hashomer key. Genotypes at the SAA1 locus (isoforms α, β, and γ) were determined in all patients. The SAA1 13C/T polymorphism of the SAA1 promotor was analyzed in a subset of cases.

Results

The male:female ratio (154:123, or 1.3) was higher among patients with amyloidosis (40:22, or 1.8) compared with patients without amyloidosis (114:101, or 1.1). Logistic regression analysis showed that homozygosity for the M694V allele (odds ratio [OR] 4.27, 95% confidence interval [95% CI] 2.01–9.07), the presence of the SAAα/α genotype (OR 2.99, 95% CI 1.47–6.09), the occurrence of arthritis attacks (OR 2.43, 95% CI 1.17–5.06), and male sex (OR 1.73, 95% CI 0.90–3.33) were significantly and independently associated with renal amyloidosis. Disease severity was mainly influenced by MEFV mutations and was not associated with genotypes at the SAA1 locus. The SAA1 13T allele was rare, being associated mainly with the SAA γ isoform, and not related to renal amyloidosis.

Conclusion

Overall, disease severity and the development of amyloidosis in FMF are differentially affected by genetic variations within and outside the MEFV gene.

REFERENCES

1 Sohar E, Gafni J, Pras M, Heller J. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 1967; 43: 227–53.
10.1016/0002-9343(67)90167-2
CAS PubMed Web of Science® Google Scholar
2 Pras M, Bronshpigel N, Zemer D, Gafni J. Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. Johns Hopkins Med J 1982; 150: 22–6.
CAS PubMed Web of Science® Google Scholar
3 Booth DR, Gillmore JD, Booth SE, Pepys MB, Hawkins PN. Pyrin/marenostrin mutations in familial Mediterranean fever. QJM 1998; 91: 603–6.
10.1093/qjmed/91.9.603
CAS PubMed Web of Science® Google Scholar
4 Bernot A, da Silva C, Petit JL, Cruaud C, Caloustian C, Castet V, et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever. Hum Mol Genet 1998; 7: 1317–25.
10.1093/hmg/7.8.1317
CAS PubMed Web of Science® Google Scholar
5 Aksentijevich I, Torosyan Y, Samuels J, Centola M, Pras E, Chae JJ, et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency in the Ashkenazi Jewish population. Am J Hum Genet 1999; 64: 949–62.
10.1086/302327
CAS PubMed Web of Science® Google Scholar
6 Gershoni-Baruch R, Shinawi M, Kasinetz L, Badarna K, Brik R. Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet 2001; 9: 634–7.
10.1038/sj.ejhg.5200672
CAS PubMed Web of Science® Google Scholar
7 Shinawi M, Brik R, Berant M, Kasinetz L, Gershoni-Baruch R. Familial Mediterranean fever: high gene frequency and heterogeneous disease among an Israeli-Arab population. J Rheumatol 2000; 27: 1492–5.
CAS PubMed Web of Science® Google Scholar
8 Dewalle M, Domingo C, Rozenbaum M, Ben-Chetrit E, Cattan D, Bernot A, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). Eur J Hum Genet 1998; 6: 95–7.
10.1038/sj.ejhg.5200170
CAS PubMed Web of Science® Google Scholar
9 Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reinert P, et al. MEFV-gene analysis in Armenian patients with familial Mediterranean fever: diagnostic value and unfavourable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. Am J Hum Genet 1999; 65: 88–97.
10.1086/302459
CAS PubMed Web of Science® Google Scholar
10 Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A, et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 1999; 7: 287–92.
10.1038/sj.ejhg.5200303
CAS PubMed Web of Science® Google Scholar
11 Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, Pras M, et al. MEFV mutation analysis of patients suffering from amyloidosis in familial Mediterranean fever. Amyloid 1999; 6: 1–6.
10.3109/13506129908993281
CAS PubMed Web of Science® Google Scholar
12 Brik R, Shinawi M, Kepten I, Berant M, Gershoni-Baruch R. Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 1999; 103: e70.
10.1542/peds.103.5.e70
CAS PubMed Web of Science® Google Scholar
13 Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Koziol E, et al. Phenotype-genotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol 2000; 27: 1703–7.
CAS PubMed Web of Science® Google Scholar
14 Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002; 10: 145–9.
10.1038/sj.ejhg.5200776
CAS PubMed Web of Science® Google Scholar
15 Stoffman N, Magal N, Shohat T, Lotan R, Koman S, Oron A, et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 2000; 8: 307–10.
10.1038/sj.ejhg.5200446
CAS PubMed Web of Science® Google Scholar
16 Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001; 102: 272–6.
10.1002/ajmg.1438
CAS PubMed Web of Science® Google Scholar
17 Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001–5.
10.1056/NEJM198604173141601
CAS PubMed Web of Science® Google Scholar
18 Yalcinkaya F, Akar N, Misirlioglu M. Familial Mediterranean fever: amyloidosis and the Val726Ala mutation [letter]. N Engl J Med 1998; 338: 993–4.
10.1056/NEJM199804023381414
CAS PubMed Web of Science® Google Scholar
19 Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum 1996; 26: 612–27.
10.1016/S0049-0172(96)80012-6
CAS PubMed Web of Science® Google Scholar
20 Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mudjoyan E, et al. Identification of MEFV-independent genetic factors for familial Mediterranean fever. Am J Hum Genet 2000; 67: 1136–43.
CAS PubMed Web of Science® Google Scholar
21 Liepnicks J, Kluve-Beckerman B, Benson M. Characterization of amyloid A protein in secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta 1995; 1270: 81–6.
10.1016/0925-4439(94)00076-3
PubMed Web of Science® Google Scholar
22 Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugune S, et al. A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995; 4: 1083–7.
10.1093/hmg/4.6.1083
CAS PubMed Web of Science® Google Scholar
23 Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, et al. Influence of genotypes at the SAA1 and SAA2 loci on the development and length of latent period of secondary AA amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999; 105: 360–6.
CAS PubMed Web of Science® Google Scholar
24 Moriguchi M, Terai C, Koseki Y, Kaneko H, Uesato M, Nishikawa T, et al. Genotypes at the SAA1 locus correlate with the clinical severity of AA amyloidosis. Amyloid 2001; 8: 115–20.
10.3109/13506120109007354
CAS PubMed Web of Science® Google Scholar
25 Booth D, Booth S, Gillmore J, Hawkins P, Pepys M. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998; 5: 262–5.
10.3109/13506129809007299
CAS PubMed Web of Science® Google Scholar
26 Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, Uesato M, et al. A novel single-nucleotide polymorphism at the 5′-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum 2001; 44: 1266–72.
10.1002/1529-0131(200106)44:6<1266::AID-ART218>3.0.CO;2-3
CAS PubMed Web of Science® Google Scholar
27 Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879–85.
10.1002/art.1780401023
CAS PubMed Web of Science® Google Scholar
28 Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998; 75: 216–9.
10.1002/(SICI)1096-8628(19980113)75:2<216::AID-AJMG20>3.0.CO;2-R
CAS PubMed Web of Science® Google Scholar
29 Gershoni-Baruch R, Kepten I, Shinawi M, Brik R. Direct detection of common mutations in familial mediterranean fever gene (MEFV) using naturally occurring and primer mediated restriction fragment analysis. Hum Mutation in brief 1999; 257 (online).
Google Scholar
30 Gershoni-Baruch R, Brik R, Shinawi M, Lidar M, Livneh A. Male gender coupled with articular manifestations cause a fourfold increase in susceptibility to amyloidosis in FMF patients homozygous for the M694V-MEFV mutation. J Rheumatol 2003; 30: 308–12.
PubMed Web of Science® Google Scholar
31 Touitou I, Picot MC, Domingo C, Notarnicola C, Cattan D, Demaille J, et al. The MICA region determines the first modifier locus in familial Mediterranean fever. Arthritis Rheum 2001; 44: 163–9.
10.1002/1529-0131(200101)44:1<163::AID-ANR20>3.0.CO;2-Z
CAS PubMed Web of Science® Google Scholar
32 De Berr FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2: 231–4.
10.1016/S0140-6736(82)90321-X
PubMed Web of Science® Google Scholar
33 Maury CP, Wegelius O. Clinical value of serum amyloid A and C-reactive protein measurements in secondary amyloidosis. Int J Tissue React 1985; 7: 405–7.
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume48, Issue4

April 2003

Pages 1149-1155

The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Related

Information